CONFERENCE AGENDA
KEYNOTE
Marc Siladi
EXECUTIVE DIRECTOR
Strateos
Tuesday, Nov. 8th at 10 AM EST
Beyond Digital: Leveraging Digital Transformation to Scale Impact
Abstract:
In this presentation Strateos will equip the audience with a deeper understanding of the path to automation, while establishing the value of a transformed unit. We will review the new enablers within LodeStar and how they are leveraged to absorb both routine and non-routine lab work. In the end the audience will understand not only the transformation available, but also the scaled impact realized.
Nikki Dare
SOLUTION AREA MANAGER, KATALYST D2D
ACD/Labs
Wednesday, Nov. 9th at 10 AM EST
Experiment Design and Automation of Analytical Data Processing and Management in HTE
Abstract:
Automation and high throughput synthesis (more generally referred to as High Throughput Experimentation—HTE), with the help of robotics, has allowed scientists to significantly increase experiment output. This also includes the amount of analytical data that can be collected in shorter periods of time. Current solutions for analytical data processing in HTE require tedious and error prone transfer of data, including experimental designs, between multiple software systems, and manual association of analytical results with experiments. We will present purpose-built HTE software that not only integrates with existing hardware and software to bring all design, planning, and execution into a single interface; it also automates targeted analytical data processing and association of analytical data to experimental design.
CEO
Stanislav Bashkyrtsev
Elsci Life Sciences
Wednesday, Nov. 9th at 11 AM EST
Modernizing Software Processes in Life Sciences
Abstract:
Life Sciences IT is quite isolated from the rest of the IT world. On the one hand it's pierced by advanced technology like Robotics/AI/ML/HPC; on the other hand lots of scientists still use spreadsheets on a daily basis, and most software looks and feels archaic.
I'd like to speculate on why this is the case and what we can do to improve the situation. We'll talk about:
• Modern software processes, and how they differ from what Big Pharma is doing
• UX, and how high-quality software should look and behave
• How scientists can help IT; and what's required on the IT side
Teodoro Laino
RESEARCH MANAGER
IBM
Wednesday, Nov. 9th at 11:30 AM EST
Accelerating Chemistry with Cloud-based AI Driven Autonomous Labs
Teodoro Laino, Matteo Manica, Alain Claude Vaucher, Aleksandros Sobczyk, Amol Thakkar, Carlo Baldassari, Artem Leonov, Alessandra Toniato, Heiko Wolf, Federico Zipoli IBM Research Europe, CH-8803 Rüschlikon, Switzerland teo@zurich.ibm.com
Abstract:
One of the greatest contributions of chemistry is the ability to create and design new molecules. The synthesis of many novel molecular structures has relied heavily on the application of domain knowledge acquired over many years of laboratory work. But most synthetic success stories are preceded by long hours of unproductive repetitive experiments. The development of automation systems within the last two decades to help chemists with mundane laboratory tasks has contributed to the mitigation of this issue. There are some areas, like high-throughput chemistry, where these technologies have proven to be particularly useful, but automating general-purpose jobs is still a very difficult problem to solve. Operators in the chemical industry must create specialized software for each operation, with the goal of codifying a particular chemical process. Meanwhile, Artificial Intelligence (AI) has established itself as a valuable complement to human knowledge and creativity in organic chemistry, performing tasks such as predicting chemical reactions [1-2], retrosynthetic routes [3], digitizing chemical literature [4], and predicting experimental procedures for previously unseen chemistry [5]. In this talk, I'll talk about the lessons learned and the opportunities of a fully autonomous laboratory run by artificial intelligence and accessible through the cloud [6].
•[1] IBM Research Europe, Chem. Sci., 2018, 9, 6091-6098
•[2] IBM Research Europe, ACS Cent. Sci. 2019, 5, 9, 1572-1583
•[3] IBM Research Europe, Chem. Sci., 2020, 11, 3316-3325
•[4] IBM Research Europe, Nat. Comm., 11, 2601 (2020)
•[5] IBM Research Europe, Nat. Comm., 12, 2573 (2021) [6] https://rxn.res.ibm.com
Eugénie Romero
MANAGER - HTE CENTER
French Atomic Energy Commission
Wednesday, Nov. 9th at 1:30 PM EST
High-Throughput Experimentation: Between Innovation and Accessibility
Abstract:
For years, High-Throughput Experimentation (HTE) has been applied to organic chemistry for reaction optimization and reaction discovery as a powerful tool for time and cost reduction. Suppose this technology has been first developed by and for industry and used as a routine method today. In that case, some academic researchers, including those in Europe, still face the accessibility of HTE as a general and daily used technology. The main reason is probably the expensive cost of such facilities set-up, which generally involves automation with robots, dedicated research teams, and costly analytical instrumentation. It is now the challenge of the HTE practitioners to help scientists implement this valuable methodology in their research programs and highlight the accessibility of HTE with a minimum of instrumentation and cost to enable the highest number of organic chemists to accelerate their research.
Beyond Digital: Leveraging Digital Transformation to Scale Impact
Abstract:
In this presentation Strateos will equip the audience with a deeper understanding of the path to automation, while establishing the value of a transformed unit. We will review the new enablers within LodeStar and how they are leveraged to absorb both routine and non-routine lab work. In the end the audience will understand not only the transformation available, but also the scaled impact realized.
Adam Wheeler
DIRECTOR OF MARKETING
Strateos
Tuesday, Nov. 8th at 10 AM EST
Beyond Digital: Leveraging Digital Transformation to Scale Impact
Abstract:
In this presentation Strateos will equip the audience with a deeper understanding of the path to automation, while establishing the value of a transformed unit. We will review the new enablers within LodeStar and how they are leveraged to absorb both routine and non-routine lab work. In the end the audience will understand not only the transformation available, but also the scaled impact realized.
Successful Implementation of Automated Workflows in Chemistry versus Life Sciences: It's the Little Things
